Liposomal Amphotericin B Shows Poor Antifungal Activity Against Candida Tropicalis Biofilms L.J

Total Page:16

File Type:pdf, Size:1020Kb

Liposomal Amphotericin B Shows Poor Antifungal Activity Against Candida Tropicalis Biofilms L.J Liposomal amphotericin B shows poor antifungal activity against Candida tropicalis biofilms L.J. Marcos- Zambrano1,2 ,P. Escribano1,2,3, E. Bouza1,2,3,4, J. Guinea1,2,3,4 EP0063 1 Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 2 Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. 3 CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain. 4 Medicine Department, Faculty of Medicine, Universidad Complutense de Madrid INTRODUCTION RESULTS Candidemia caused by Candida tropicalis present high mortality rates and is often associated with biofilm formation Most of isolates were classified as high- The three drugs showed activity against the isolates in planktonic form, with on implanted medical devices. biofilm forming according to crystal violet micafungin showing the highest activity (P<0.001). Echinocandins and amphotericin B have shown potent in assay (83%) and showed moderate L-AmB showed the lowest antibiofilm activity (P<0.05). MYC and AmB showed similar vitro antibiofilm activity against C.albicans biofilm, but little is metabolic activity (56%) according to activity when the SMIC50 endpoint was used whereas MYC was the most active agent known about the activity against C. tropicalis biofilms. XTT reduction assay. when the SMIC80 endpoint was used (P<0.001). OBJECTIVE Table 1. Antifungal activity of MYC, AmB and L-AmB against C. tropicalis isolates in plancktonic and sessile forms; SMIC and SMIC are provided for the latter forms. We studied the biofilm production and antifungal 50 80 susceptibility of 54 C. tropicalis isolates causing candidemia (2007 to 2015) to micafungin, amphotericin B, and liposomal Planktonic MIC (mg/L) SMIC50 (mg/L) SMIC80 (mg/L) amphotericin B (Ambisome ®) MYC AmB L-AmB MYC AmB L-AmB MYC AmB L-AmB METHODS Geometric mean 0.026 0.53 0.22 0.72 0.87 1.80 9.82 14.07 30.39 54 C. tropicalis isolates from blood cultures P < 0.05 P < 0.05 P < 0.05 Molecular identification by amplification of the C. tropicalis biofilms were formed by In contrast, the exposure to MYC promoted significant alterations in the biofilm structure consisting ITS1-5.8S-ITS2 region a dense and thick web of hyphae. on a reduction in the number of hyphae, and the presence of swollen blastospores. L-AmB induced subtle changes on The differences are consistent with the antifungal susceptibility testing as both the SMIC50 and the biofilm structure. SMIC80 were much lower for MYC than for both forms of amphotericin B. Classification according to biofilm production (a) (b) (c) Biomass (Crystal violet) Metabolic activity (XTT) Low, moderate and high Low, moderate, and high biofilm forming metabolic activity Antifungal susceptibility to Micafungin (MYC), Amphotericin B (AmB), and liposomal amphotericin B (L-AmB) EUCAST XTT (Planktonic form) (Biofilm form) 20µm 20µm 20µm Figure 1. SEM images showing the impact of the exposure of the biofilm formed by the C. tropicalis strain. (a) Untreated control; (b) Isolate exposed to MYC [SMIC80=0.031 mg/L]; (c) Isolate exposed to L-AmB [SMIC80=16 mg/L]. 2000 X magnification. Scanning Electron Microscopy (SEM) CONCLUSIONS Treated and non-treated biofilms Micafungin was the drug showing the highest antibiofilm activity against C. tropicalis. L-AmB showed poor activity against C. tropicalis biofilms. This study was supported by FIS PI14/00740 .
Recommended publications
  • Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep
    animals Article Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep Shashwati Mathurkar 1,*, Preet Singh 2 ID , Kavitha Kongara 2 and Paul Chambers 2 1 1B, He Awa Crescent, Waikanae 5036, New Zealand 2 School of Veterinary Sciences, College of Sciences, Massey University, Palmerston North 4474, New Zealand; [email protected] (P.S.); [email protected] (K.K.); [email protected] (P.C.) * Correspondence: [email protected]; Tel.: +64-221-678-035 Received: 13 June 2018; Accepted: 16 July 2018; Published: 18 July 2018 Simple Summary: Scarcity of non-steroidal anti-inflammatory drugs (NSAID) to minimise the pain in sheep instigated the current study. The aim of this study was to know the pharmacokinetic parameters of salicylic acid in New Zealand sheep after administration of multiple intravenous and oral doses of sodium salicylate (sodium salt of salicylic acid). Results of the study suggest that the half-life of the drug was shorter and clearance was faster after intravenous administration as compared to that of the oral administration. The minimum effective concentration required to produce analgesia in humans (16.8 µL) was achieved in sheep for about 0.17 h in the current study after intravenous administration of 100 and 200 mg/kg body weight of sodium salicylate. However, oral administration of these doses failed to achieve the minimum effective concentration as mentioned above. This study is of significance as it adds valuable information on pharmacokinetics and its variation due to breed, species, age, gender and environmental conditions.
    [Show full text]
  • Original Article Interaction of Candida Albicans with Fluconazole
    International Journal of Medical Laboratory 2020;7(2):110-120. Original Article Interaction of Candida albicans with Fluconazole/ Clotrimazole: Effect on Hyphae Formation and Expression of Hyphal Wall Protein 1 Sakineh Jam Shahriari1 M.Sc., Fahimeh Alizadeh1* Ph.D. Alireza Khodavandi2 Ph.D. 1Department of Microbiology, Yasooj Branch, Islamic Azad University, Yasooj, Iran. 2Department of Biology, Gachsaran Branch, Islamic Azad University, Gachsaran, Iran. A B S T R A C T Article history Background and Aims: Candida albicans (C. albicans) is the most common Received 20 May 2019 opportunistic human pathogen. Therapeutic options for Candida infections are Accepted 22 Jul 2019 limited to available antifungal drugs. The aim of this study was to investigate Available online 30 May 2020 the effects of fluconazole/clotrimazole (FLU/CLT) on C. albicans hyphae Key words formation. Candida albicans Materials and Methods: We have established the effectiveness of the Clotrimazole combination of FLU/CLT on C. albicans hyphae formation. Interaction of C. Fluconazole Hyphae albicans with combination of FLU/CLT was performed using the CLSI guidelines and time-killing curves. We investigated the anti-hyphal activities of combination of FLU/CLT against C. albicans using XTT and crystal violet assays as well as scanning electron microscopy and expression of HWP1 gene. Results: The interaction of C. albicans with FLU/CLT resulted in synergistic, partial synergistic and indifferent effects. The interaction of FLU/CLT were confirmed by time-killing curves. FLU/CLT combined resulted in the reduction of metabolic activity and hyphae formation in C. albicans. Images taken by scanning electron microscopy indicated the effectiveness on hyphae disruption.
    [Show full text]
  • Eczema Low Cost (TALC) David Chandler 13 in the Community Najeeb Ahmad Safdar & Jane Sterling 6 ABSTRACTS ESSENTIAL DRUGS in DERMATOLOGY Journal Extracts and 1
    An International Journal for Community Skin Health EDITORIAL: PUBLIC HEALTH AND SKIN DISEASE R J Hay DM FRCP record which is often unrecognised. For International Foundation of instance, in the early part of the twenti- Dermatology eth century many countries had policies Professor of Dermatology for the control of scalp ringworm which Faculty of Medicine and Health Sciences ranged from school exclusion orders to special treatment facilities. It resulted in Queen’s University, Belfast, UK partial control but, in the absence of an effective remedy, elimination remained ost of the work of dermato- a distant goal. With the discovery of logists is concerned with the drug, griseofulvin, the potential to the treatment of individ- provide a wider programme based on Mual patients to the highest standards the treatment of communities became achievable with the facilities and skills possible and, in some areas, there was a available. However, it is seldom possible concerted effort to eliminate tinea capi- to apply this to large populations in tis using control teams. Afghan refugee child most parts of the developing world, par- Yaws and leprosy are further exam- ticularly where the lack of resources and ples of diseases where control measures, sparse populations make the adoption of backed by international collaboration, this model of health care unattainable. have focused on elimination of infection In assessing the needs for these groups a by early identification of cases and con- different approach is necessary. tacts and mass drug treatment. Public Health and Skin Skin Disease and the Western Disease World Dermatological public health has sel- In recent years, the focus of public dom been prioritised as a key objec- health in 'western world' dermatology tive in the overall management of has concentrated on the control of the At a Health Centre, Afgooye, Somalia skin diseases, although it has a strong modern epidemic of a non-infectious Photos: Murray McGavin CONTENTS J Comm Dermatol 2005; 2: 1–16 Issue No.
    [Show full text]
  • 204684Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204684Orig1s000 OFFICE DIRECTOR MEMO Deputy Office Director Decisional Memo Page 2 of 17 NDA 204,684 Miltefosine Capsules 1. Introduction Leishmania organisms are intracellular protozoan parasites that are transmitted to a mammalian host by the bite of the female phlebotomine sandfly. The main clinical syndromes are visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucosal leishmaniasis (ML). VL is the result of systemic infection and is progressive over months or years. Clinical manifestations include fever, hepatomegaly, splenomegaly, and bone marrow involvement with pancytopenia. VL is fatal if untreated. Liposomal amphotericin B (AmBisome®) was FDA approved in 1997 for the treatment of VL. CL usually presents as one or more skin ulcers at the site of the sandfly bite. In most cases, the ulcer spontaneously resolves within several months, leaving a scar. The goals of therapy are to accelerate healing, decrease morbidity and decrease the risk of relapse, local dissemination, or mucosal dissemination. There are no FDA approved drugs for the treatment of CL. Rarely, CL disseminates from the skin to the naso-oropharyngeal mucosa, resulting in ML. ML can also develop some time after CL spontaneous ulcer healing. The risk of ML is thought to be highest with CL caused by the subgenus Viannia. ML is characterized in the medical literature as progressive with destruction of nasal and pharyngeal structures, and death may occur due to complicating aspiration pneumonia. There are no FDA approved drugs for the treatment of ML. Paladin Therapeutics submitted NDA 204, 684 seeking approval of miltefosine for the treatment of VL caused by L.
    [Show full text]
  • Systemic Antifungal Drug Use in Belgium—
    Received: 7 October 2018 | Revised: 28 March 2019 | Accepted: 14 March 2019 DOI: 10.1111/myc.12912 ORIGINAL ARTICLE Systemic antifungal drug use in Belgium—One of the biggest antifungal consumers in Europe Berdieke Goemaere1 | Katrien Lagrou2,3* | Isabel Spriet4,5 | Marijke Hendrickx1 | Eline Vandael6 | Pierre Becker1 | Boudewijn Catry6,7 1BCCM/IHEM Fungal Collection, Service of Mycology and Aerobiology, Sciensano, Summary Brussels, Belgium Background: Reports on the consumption of systemic antifungal drugs on a national 2 Department of Microbiology and level are scarce although of high interest to compare trends and the associated epi- Immunology, KU Leuven, Leuven, Belgium 3Clinical Department of Laboratory demiology in other countries and to assess the need for antifungal stewardship Medicine, National Reference Centre for programmes. Mycosis, University Hospitals Leuven, Leuven, Belgium Objectives: To estimate patterns of Belgian inpatient and outpatient antifungal use 4Department of Pharmaceutical and and provide reference data for other countries. Pharmacological Sciences, KU Leuven, Methods: Consumption records of antifungals were collected in Belgian hospitals Leuven, Belgium between 2003 and 2016. Primary healthcare data were available for the azoles for 5Pharmacy Department, University Hospitals Leuven, Leuven, Belgium the period 2010-2016. 6 Healthcare‐Associated Infections and Results: The majority of the antifungal consumption resulted from prescriptions of Antimicrobial Resistance, Sciensano, Brussels, Belgium fluconazole and itraconazole in the ambulatory care while hospitals were responsible 7Faculty of Medicine, Université Libre de for only 6.4% of the total national consumption and echinocandin use was limited. Bruxelles (ULB), Brussels, Belgium The annual average antifungal consumption in hospitals decreased significantly by Correspondence nearly 25% between 2003 and 2016, due to a decrease solely in non-university hos- Berdieke Goemaere, Sciensano, Mycology pitals.
    [Show full text]
  • Updates in Ocular Antifungal Pharmacotherapy: Formulation and Clinical Perspectives
    Current Fungal Infection Reports (2019) 13:45–58 https://doi.org/10.1007/s12281-019-00338-6 PHARMACOLOGY AND PHARMACODYNAMICS OF ANTIFUNGAL AGENTS (N BEYDA, SECTION EDITOR) Updates in Ocular Antifungal Pharmacotherapy: Formulation and Clinical Perspectives Ruchi Thakkar1,2 & Akash Patil1,2 & Tabish Mehraj1,2 & Narendar Dudhipala1,2 & Soumyajit Majumdar1,2 Published online: 2 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review In this review, a compilation on the current antifungal pharmacotherapy is discussed, with emphases on the updates in the formulation and clinical approaches of the routinely used antifungal drugs in ocular therapy. Recent Findings Natamycin (Natacyn® eye drops) remains the only approved medication in the management of ocular fungal infections. This monotherapy shows therapeutic outcomes in superficial ocular fungal infections, but in case of deep-seated mycoses or endophthalmitis, successful therapeutic outcomes are infrequent, as a result of which alternative therapies are sought. In such cases, amphotericin B, azoles, and echinocandins are used off-label, either in combination with natamycin or with each other (frequently) or as standalone monotherapies, and have provided effective therapeutic outcomes. Summary In recent times, amphotericin B, azoles, and echinocandins have come to occupy an important niche in ocular antifungal pharmacotherapy, along with natamycin (still the preferred choice in most clinical cases), in the management of ocular fungal infections.
    [Show full text]
  • Enhanced Activity of Antifungal Drugs Using Natural Phenolics Against Yeast Strains of Candida and Cryptococcus N.C.G.Faria1, J.H
    Letters in Applied Microbiology ISSN 0266-8254 ORIGINAL ARTICLE Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus N.C.G.Faria1, J.H. Kim3, L.A.P. Gonc¸alves2, M. de L. Martins1, K.L. Chan3 and B.C. Campbell3 1 Instituto de Higiene e Medicina Tropical ⁄ CREM, Universidade Nova de Lisboa, Portugal 2 Instituto de Higiene e Medicina Tropical ⁄ CEAUL, Universidade Nova de Lisboa, Portugal 3 Plant Mycotoxin Research Unit, Western Regional Research Center, ARS-USDA, Albany, CA, USA Keywords Abstract amphotericin B, phenolic, synergism, triazole. Aims: Determine whether certain, natural phenolic compounds enhance activ- Correspondence ity of commercial antifungal drugs against yeast strains of Candida and Crypto- Bruce C. Campbell, Plant Mycotoxin Research coccus neoformans. Unit, Western Regional Research Center, Methods and Results: Twelve natural phenolics were examined for fungicidal USDA-ARS, 800 Buchanan Street, Albany, CA activity against nine reference strains of Candida and one of C. neoformans. Six 94710, USA. compounds were selected for synergistic enhancement of antifungal drugs, E-mail: [email protected] amphotericin B (AMB), fluconazole (FLU) and itraconazole (ITR). Matrix assays 2010 ⁄ 1438: received 19 August 2010, revised of phenolic and drug combinations conducted against one reference strain, each, 14 February 2011 and accepted 15 February of Candida albicans and C. neoformans showed cinnamic and benzoic acids, thy- 2011 mol, and 2,3- and 2,5-dihydroxybenzaldehydes (-DBA) had synergistic interac- tions depending upon drug and yeast strain. 2,5-DBA was synergistic with doi:10.1111/j.1472-765X.2011.03032.x almost all drug and strain combinations.
    [Show full text]
  • Antifungal Drugs
    Antifungal Drugs Antifungal or antimycotic drugs are those agents used to treat diseases caused by fungus. Fungicides are drugs which destroy fungus and fungistatic drugs are those which prevent growth and multiplication of fungi. Collectively these drugs are often referred to as antimycotic or antifungal drugs. General characteristics of fungus: Fungi of medical significance are of two groups: Yeast Unicellular (Candida, Crytococcus) Molds Multicellular; filamentous consist of hyphae (Aspergillus, Microsporum, Trichophyton) They are eukaryotic i.e. they have well defined nucleus and other nuclear materials. They are made of thin threads called hyphae. The hyphae have a cell wall (like plant cells) made of a material called chitin. The hyphae are often multinucleate. They do not have chlorophyll, can’t make own food by photosynthesis, therefore derive nutrients by means of saprophytic or parasitic existence. Cell membrane is made up of ergosterol. Types of fungal infections: Fungal infections are termed as mycoses and in general can be divided into: Superficial infections: Affecting skin, nails, scalp or mucous membranes; e.g. Tinea versicolor Dermatophytosis: Fungi that affect keratin layer of skin, hair and nail; e.g. Tinea pedis, rign worm infection. Candidiasis: Yeast infections caused by (Malassezia pachydermatis), oral thrush (oral candidiasis), vulvo-vaginitis, nail infection. Systemic/Deep infections: Affecting deeper tissues and organ they usually affect lungs, heart and brain leading to pneumonia, endocarditis and meningitis. Systemic infections are associated with immunocompromised patients, these diseases are serious and often life threatening due to the organ involved. Some of the serious systemic fungal infections in man are candidiasis, cryptococcal meningitis, pulmonary aspergillosis.
    [Show full text]
  • The Role of Amphotericin B Alone and in Combination with Different Antibiotics and Antifungals on Biofilms Produced by Candida Species
    FABAD J. Pharm. Sci., 45, 2, 117-124, 2020 RESEARCH ARTICLE The Role of Amphotericin B Alone and in Combination with Different Antibiotics and Antifungals on Biofilms Produced by Candida Species Mayram HACIOGLU*° , Ozlem OYARDI** , Berna OZBEK-CELIK*** The Role of Amphotericin B Alone and in Combination with Amfoterisin B’nin Tek Başına ve Çeşitli Antibiyotik ve Different Antibiotics and Antifungals on Biofilms Produced Antifungallerle Birlikte Candida Biyofilmleri Üzerine Etkisi by Candida Species SUMMARY ÖZ Biofilm formation by Candida species is highly resistant to commonly Biyofilm oluşumu Candida türlerinde antifungallere daha dirençli used antifungal agents and is difficult to treat. Therefore, this study olmalarını sağladığından tedavisi güç enfeksiyonlara neden focused on effectiveness of combination therapy against Candida olmaktadır. Bu amaçla, bu çalışmada Candida biyofilmlerine biofilms. The antimicrobial activities of amphotericin B (1 µg/ karşı kombinasyon tedavisinin etkinliği araştırılmıştır. ml or 10 µg/ml) alone or in combination with various antibiotics Amfoterisin B’nin (1 µg / ml veya 10 µg / ml) tek başına veya (doxycycline (20 µg/ml), tigecycline (20 µg/ml), colistin (30 µg/ml), çeşitli antibiyotiklerle [(doksisiklin (20 µg / ml), tigesiklin (20 µg / rifampicin (120 µg/ml), ciprofloxacin (20 µg/ml)) or antifungals ml), kolistin (30 µg / ml), rifampisin (120 µg / ml), siprofloksasin (clotrimazole (2.5 µg/ml), anidulafungin (10 µg/ml), caspofungin (20 µg / ml)] veya çeşitli antifungaller [(klotrimazol (2.5 µg / ml), (10 µg/ml), itraconazole (2.5 µg/ml) and fluconazole (10 µg/ml)) anidulafungin (10 µg / ml), kaspofungin (10 µg / ml), itrakonazol were investigated against fungal biofilms produced by C. albicans (2.5 µg / ml), flukonazol (10 µg/ml)] ile kombinasyonlarının SC5314, C.
    [Show full text]
  • Sodium Salicylate Influences the Pseudomonas Aeruginosa Biofilm
    International Journal of Molecular Sciences Article Sodium Salicylate Influences the Pseudomonas aeruginosa Biofilm Structure and Susceptibility Towards Silver Erik Gerner 1,2,3,* , Sofia Almqvist 2 , Peter Thomsen 1 , Maria Werthén 1,3 and Margarita Trobos 1,3,* 1 Department of Biomaterials, The Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden; [email protected] (P.T.); [email protected] (M.W.) 2 Mölnlycke Health Care AB, 415 02 Gothenburg, Sweden; sofi[email protected] 3 Center for Antibiotic Resistance Research (CARe), University of Gothenburg, 405 30 Gothenburg, Sweden * Correspondence: [email protected] (E.G.); [email protected] (M.T.) Abstract: Hard-to-heal wounds are typically infected with biofilm-producing microorganisms, such as Pseudomonas aeruginosa, which strongly contribute to delayed healing. Due to the global challenge of antimicrobial resistance, alternative treatment strategies are needed. Here, we investigated whether inhibition of quorum sensing (QS) by sodium salicylate in different P. aeruginosa strains (QS-competent, QS-mutant, and chronic wound strains) influences biofilm formation and tolerance to silver. Biofilm formation was evaluated in simulated serum-containing wound fluid in the presence or absence of sodium salicylate (NaSa). Biofilms were established using a 3D collagen-based biofilm model, collagen coated glass, and the Calgary biofilm device. Furthermore, the susceptibility of 48-h-old biofilms formed by laboratory and clinical strains in the presence or absence of NaSa towards silver was evaluated by assessing cell viability. Biofilms formed in the presence of NaSa were more susceptible to silver and contained reduced levels of virulence factors associated with biofilm development than those formed in the absence of NaSa.
    [Show full text]
  • Ambisome® (Amphotericin B) Liposome for Injection
    AmBisome® (amphotericin B) liposome for injection DESCRIPTION AmBisome® for Injection is a sterile, non-pyrogenic lyophilized product for intravenous infusion. Each vial contains 50 mg of amphotericin B, USP, intercalated into a liposomal membrane consisting of approximately 0.64 mg alpha tocopherol, USP; 52 mg cholesterol, NF; 84 mg distearoyl phosphatidylglycerol, sodium salt; 213 mg hydrogenated soy phosphatidylcholine. In addition, 27 mg disodium succinate hexahydrate and 900 mg sucrose, NF are used as a buffer. AmBisome may contain hydrochloric acid and/or sodium hydroxide as pH adjusters. Following reconstitution with Sterile Water for Injection, USP, the resulting pH of the suspension is between 5-6. AmBisome is a true single bilayer liposomal drug delivery system. Liposomes are closed, spherical vesicles created by mixing specific proportions of amphophilic substances such as phospholipids and cholesterol so that they arrange themselves into multiple concentric bilayer membranes when hydrated in aqueous solutions. Single bilayer liposomes are then formed by microemulsification of multilamellar vesicles using a homogenizer. AmBisome consists of these unilamellar bilayer liposomes with amphotericin B intercalated within the membrane. Due to the nature and quantity of amphophilic substances used, and the lipophilic moiety in the amphotericin B molecule, the drug is an integral part of the overall structure of the AmBisome liposomes. AmBisome contains true liposomes that are less than 100 nm in diameter. A schematic depiction of the liposome is presented below. Note: Liposomal encapsulation or incorporation into a lipid complex can substantially affect a drug’s functional properties relative to those of the unencapsulated drug or non-lipid associated drug. In addition, different liposomal or lipid-complex products with a common active ingredient may vary from one another in the chemical composition and physical form of the lipid component.
    [Show full text]
  • Theranostics CPX Targeting DJ-1 Triggers ROS-Induced Cell Death and Protective Autophagy in Colorectal Cancer
    Theranostics 2019, Vol. 9, Issue 19 5577 Ivyspring International Publisher Theranostics 2019; 9(19): 5577-5594. doi: 10.7150/thno.34663 Research Paper CPX Targeting DJ-1 Triggers ROS-induced Cell Death and Protective Autophagy in Colorectal Cancer Jing Zhou1,2*, Lu Zhang2*, Meng Wang2*, Li Zhou2, Xuping Feng2, Linli Yu1, Jiang Lan2, Wei Gao2, 1 1 2 3 1 Chundong Zhang , Youquan Bu , Canhua Huang , Haiyuan Zhang , Yunlong Lei 1. Department of Biochemistry and Molecular Biology, Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing, 400016, P.R.China 2. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, P.R. China 3. Key Laboratory of Tropical Diseases and Translational Medicine of Ministry of Education & Department of Neurology, the First Affiliated Hospital of Hainan Medical University, Haikou, P. R. China *These authors contributed equally to this work. Corresponding author: Prof. Yunlong Lei, Department of Biochemistry and Molecular Biology, and Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing 400016, P. R. China. Tel: +86 13648323625, Email: [email protected], [email protected]; Prof. Haiyuan Zhang, Key Laboratory of Tropical Diseases and Translational Medicine of Ministry of Education & Department of Neurology, the First Affiliated Hospital of Hainan Medical University, Haikou, P. R. China. Tel: + 86 15027037562, Email: [email protected]. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
    [Show full text]